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Most, if not all, lymphoma subtypes display considerable heterogeneity in their
clinical and pathological characteristics, intricately linked to the underlying biolog-
ical heterogeneity.1 Indeed, the genomic landscape of lymphomas is remarkably
diverse, although an increasing number of ‘shared’ genetic lesions have recently
emerged, affecting similar mechanisms and processes that in certain instances are
Similar to the inherent clinical heterogeneity of most, if not all, lym-phoma entities, the genetic landscape of these tumors is markedlycomplex in the majority of cases, with a rapidly growing list of
recurrently mutated genes discovered in recent years by next-generation
sequencing technology. Whilst a few genes have been implied to have
diagnostic, prognostic and even predictive impact, most gene mutations
still require rigorous validation in larger, preferably prospective patient
series, to scrutinize their potential role in lymphoma diagnostics and
patient management. In selected entities, a predominantly mutated gene
is identified in almost all cases (e.g. Waldenström’s macroglobulinemia/
lymphoplasmacytic lymphoma and hairy-cell leukemia), while for the
vast majority of lymphomas a quite diverse mutation pattern is
observed, with a limited number of frequently mutated genes followed
by a seemingly endless tail of genes with mutations at a low frequency.
Herein, the European Expert Group on NGS-based Diagnostics in
Lymphomas (EGNL) summarizes the current status of this ever-evolving
field, and, based on the present evidence level, segregates mutations into
the following categories: i) immediate impact on treatment decisions, ii)
diagnostic impact, iii) prognostic impact, iv) potential clinical impact in
the near future, or v) should only be considered for research purposes. In
the coming years, coordinated efforts aiming to apply targeted next-gen-
eration sequencing in large patient series will be needed in order to elu-
cidate if a particular gene mutation will have an immediate impact on
the lymphoma classification, and ultimately aid clinical decision making.  
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ABSTRACT
important for ‘generic’ cell homeostasis (e.g. DNA repair)
while in others they are ‘lymphocyte-specific’ (e.g. antigen
receptor signaling) (Figure 1). 
Thanks to next-generation sequencing (NGS), it has
become possible to appreciate the panorama of recurrent-
ly affected genes that contribute to disease pathogenesis
and/or evolution, at least in major lymphoma subtypes.
Mounting evidence suggests that certain gene mutations
have diagnostic, prognostic and/or predictive impact.
However, for most mutations, functional in vitro validation
and confirmation in larger patient series are warranted in
order to fully elucidate their role in the pathobiology of a
particular lymphoma as well as their relevance for routine
diagnostics. 
In few circumstances, a single recurrent mutation is
identified in almost all cases of a given lymphoma and pre-
dominates by far in the genomic landscape of that partic-
ular tumor, e.g. the MYD88L265P mutation in Waldenström’s
Macroglobulinemia (WM)/lymphoplasmacytic lymphoma
(LPL)2 and the BRAFV600E mutation in hairy-cell leukemia
(HCL).3 However, for the great majority of lymphomas,
including chronic lymphocytic leukemia (CLL),4 diffuse
large B-cell lymphoma (DLBCL),5 follicular lymphoma
(FL),6 mantle cell lymphoma (MCL),7 Burkitt lymphoma
(BL),8 splenic marginal zone lymphoma (SMZL)9 and most
peripheral T-cell lymphoma (PTCL) subtypes,10-13 NGS
studies have revealed a quite diverse and complex muta-
tion pattern, with a limited number of frequently mutated
genes accompanied by a long tail of genes with low-fre-
quency mutations. In addition, while some genes are
biased to certain lymphoma entities, e.g. SF3B1mutations
in CLL,14,15 KLF2 mutations in SMZL,16-18 ID3 and TCF3
mutations in BL,19 STAT3 mutations in large granular lym-
phocyte (LGL) leukemia,11 and RHOA mutations in
angioimmunoblastic T-cell lymphoma (AITL),20,21 other
genes found recurrently mutated, such as genes involved
in DNA repair, epigenetic modification and regulation of
transcription (Figure 1), can be detected in multiple sub-
types (Table 1) and even in other cancer types.
Considering the genetic heterogeneity of lymphomas,
also highlighted by diverse results reported in hitherto pub-
lished NGS studies, it will require large-scale initiatives
encompassing thousands of patients to clarify if a specific
gene mutation has an impact on the current lymphoma
classification/diagnostics and aids clinical decision-making,
including therapy selection and response prediction. 
In an effort to summarize the current status of this ever-
evolving field and provide guidelines regarding the clinical
relevance of recent genetic findings, we have established
the European Expert Group on NGS-based Diagnostics in
Lymphomas (EGNL), with expertise in hematopathology,
molecular pathology, clinical genetics, hematology, and
oncology. The EGNL Group is supported by the European
Research Initiative on CLL (ERIC; Scientific Working
Group within the European Hematology Association,
EHA) and the European Association for
Haematopathology (EAHP). 
As our first task, we took advantage of the published lit-
erature on lymphomas to identify recurrently mutated
genes with a potential clinical relevance that were report-
ed in at least two independent studies; other genomic
aberrations, e.g. translocations and copy number aberra-
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Figure 1. Schematic overview
of recurrently affected path-
ways (A) and processes (B) in
B-cell lymphomas. Based on
references listed in Table 1. 
tions, may also be clinically relevant, though they are not
discussed in this review. As the next step, we grouped the
identified genes into the following categories based on: i)
immediate impact on treatment decisions, ii) diagnostic
impact, ii) prognostic impact, iv) potential clinical impact
in the near future, or v) interest for research purposes only.
In the end, only few genes were deemed to have direct
therapeutic or diagnostic implications, while a sizeable
proportion of genes were judged as prognostic and/or
with a potential role for patient management within the
next few years (Table 2). Though this latter category is evi-
dently difficult to define, we decided to include genes for
which recent evidence strongly suggests a diagnostic
and/or predictive role, sometimes limited to retrospective
studies, or for which targeted therapy is under develop-
ment. In the following sections, we outline our arguments
for including a particular gene in one of these categories;
highlighted genes in each category are summarized in
Table 2.  
I. Genes with immediate impact on treatment decisions 
Currently, there are few genetic lesions with document-
ed impact on therapy selection and patient management
in patients with lymphoma. This category is best exempli-
fied by TP53 aberrations in CLL.22 Such aberrations are due
to (i) deletions of chromosome 17p (covering the TP53
gene) seen in 5-10% of patients at diagnosis, which are
often associated with TP53 mutations on the remaining
allele; and, (ii) in a small fraction of CLL patients (3-6%),
mutations within the TP53 gene only.23-25 Both types of
aberrations (i.e. 17p-deletions and TP53 mutations) are
equally adverse in CLL, portending for refractoriness to
standard chemoimmunotherapy and poor overall
survival.26-29 Notably, such patients experience major clini-
cal benefit by the recently approved novel agents targeting
B-cell receptor signaling, namely, the Bruton tyrosine
kinase inhibitor ibrutinib and the phosphatidylinositol 3-
kinase delta inhibitor idelalisib that are approved for the
treatment of patients carrying either of these lesions;30
however, these patients still constitute a high-risk group
with an increased risk of disease recurrence with time. 
On these grounds, the assessment of TP53 status is
essential for clinical decision-making. Hence, sequencing
of the TP53 gene is now recommended for all CLL
patients, in addition to FISH analysis, before the start of
any line of therapy (except in the palliative situation).31,32
Indeed, testing for TP53 aberrations should be considered
companion diagnostics for signaling inhibitor treatment in
R. Rosenquist et al.
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Table 1A. Mutation frequencies in different B-cell lymphoma entities.
Pathway/cellular function CLLa MCLb BLc FLd ABC-DLBCLe GCB-DLBCLe SMZLf HCLg WMh
B-cell receptor signaling
CD79A/CD79B <1% - - 4% 10-20% <5% - - 10%
CARD11 1% - - 10% 10% 5% 4% - -
Toll-like receptor signaling
MYD88 3% - 5% - 20-30% <5% 7% - >90%
NF-κB signaling pathway
TNFPAI3 - - - 10% 20% <5% 8% - 40%*
BIRC3 <3% 5-10% - - - - 5% - -
TRAF3 <1% - - - - - 5% - -
NFKBIE <2% 5% - - <5% <5% 2% - -
Notch signaling
NOTCH1 10% 10-15% - - - - 6% - -
NOTCH2 <1% 5% - - - - 15-20% - -
Other signaling pathways
BRAF 3% - - - 4% - <1% >90% -
CXCR4 <1% - - - <10% - <1% - 25%
Transcription factors
ID3 - - 35-60% - - - - - -
TCF3 - - 10-25% - - - - - -
KLF2 - - - - - - 14% - -
DNA repair/genomic integrity
ATM 11% 40-50% - - - - 6% - -
TP53 5% 15-20% 35% 5% 10-25% 10-20% 18% - -
POT1 5% <3% - - - - <1% - -
Epigenetic modifiers
TET2 <1% <5% - - 5-10% 5-10% 3% - -
EZH2 <1% - - 10-20% - 20% <1% - -
IDH2 - - - - - - - - -
CREBBP <1% - - 50% 15-20% 40% 6% - -
EP300 <1% - 2% 10-15% <5% <10% 4% - -
CLL: chronic lymphocytic leukemia; MCL: mantle cell lymphoma; BL: Burkitt lymphoma; FL: follicular lymphoma; ABC-DLBCL: activated B-cell-like diffuse large B-cell lymphoma; GCB-DLBCL:
germinal center B-cell-like diffuse large B-cell lymphoma; SMZL: splenic marginal zone lymphoma; HCL: hairy-cell leukemia; WM: Waldenström’s Macroglobulinemia. *Genomic deletions.
aFrequencies are based on the combined cohort included in Puente et al., Nature 201586 and Landau et al., Nature 201587, though the former encompasses more general practice CLL patients
and the latter more advanced, clinical trial patients. bBased on Bea et al., PNAS 20137 Meissner et al., Blood 2013101, Rahal et al., Nat Med 201491. cBased on Schmitz et al., Nat Med 201219
dBased on Morin et al., Nat Genet 201061 Okosun et al., Nat Genet 20146 Okosun et al., Nat Genet 201660. eBased on Compagno et al., Nature 2009102, Davis et al., Nature 201093 Ngo et al.,
Nature 20115, Pasqualucci et al., Nat Genet 2011103, de Miranda et al., Blood 2014104, Bohers et al., Genes Chrom Cancer 2014105. fBased on Rossi et al., JEM 20129 Parry et al., Clin Cancer
Res 201516, Piva et al., Leukemia 201518. gBased on Tiacci et al., NEJM 201141. hBased on Treon et al., NEJM 20122 Poulain et al., Clin Cancer Res 2015106.
CLL, in order to identify patients with aberrant TP53 for
whom the new targeted therapies, described above, repre-
sent the current treatment of choice. Furthermore, the fact
that the frequency of TP53 mutations gradually increases
as the disease becomes more aggressive and chemorefrac-
tory supports the need to repeat TP53 mutation analysis
prior to any subsequent line of chemotherapy.31,32 Of note,
it has also been demonstrated that TP53 microclones at
diagnosis, i.e. subclones with a low-allelic burden detected
only by NGS but not by Sanger sequencing, were selected
by repeated rounds of chemoimmunotherapy and con-
ferred a poor outcome similar to clonal TP53mutations.33,34
If this finding is confirmed within the context of prospec-
tive clinical trials including signaling inhibitors, it is very
likely that NGS-based protocols will become the recom-
mended method for TP53 mutation screening in routine
clinical practice.
Mutations within TP53 have been described in most
other lymphoid malignancies besides CLL, albeit with
varying frequency. Although they have been linked to
poor clinical outcome in DLBCL,35 SMZL16 and MCL,36,37
this information does not currently have any impact on
treatment decisions or follow-up strategies for the individ-
ual lymphoma patient.
II. Genes of diagnostic potential 
Few lymphoma entities show a predominating, recur-
rent mutation, such as: the hotspot MYD88L265P mutation
in more than 90% of WM/LPL,2,38-40 the hotspot BRAFV600E
mutation in ~90% of HCL,41-43 and the STAT3 mutations
detected in up to 40% of LGL leukemia.11,44 None of these
mutations are pathognomonic of (i.e. exclusive to) a par-
ticular entity and can also be found in other lymphomas,
though generally at lower frequencies (Table 1). For
instance, the MYD88L265P mutation is detected in a signifi-
cant fraction of DLBCL of the activated B-cell-like subtype
(ABC DLBCL),5 as well as in primary cutaneous,45 the cen-
tral nervous system46 and testicular large B-cell lym-
phomas,47 but also in a minority of patients with CLL4,48-50
and SMZL.16,51 As another example, STAT3mutations have
been reported, albeit rarely, in immune, mainly hypoplas-
tic, bone marrow failure characterizing a subset of patients
with severe aplastic anemia or myelodysplastic
syndrome.52 Moreover, some gene mutations are mainly
found in a specific lymphoma entity at a relatively high
frequency, whereas they are rare in other subtypes, e.g.
ID3 and TCF3mutations in BL,19 KLF2 in SMZL,16-18 SF3B1
mutations in CLL,14,15 RHOA mutations in AITL and other
PTCL with a follicular helper T cell (TFH) phenotype,13,20,21,53-
59 and, very recently, the novel somatic mutations in
RRAGC encoding a Rag GTPase protein (RagC) that were
enriched in FL (16%) but were absent in other mature B-
cell lymphomas.60
That said, a pattern has started to emerge in recent years
where certain lymphoma entities ‘share’ common types of
genetic events affecting selected pathways or biological
mechanisms (Figure 1). For instance, germinal center
derived B-cell malignancies, such as DLBCL of the germi-
nal center B-cell-like type (GCB DLBCL) and FL, appear to
have higher frequencies of aberrations in epigenetic-relat-
ed genes (e.g. EZH2, CREPPB, TET2, IDH2),61,62 while other
B-cell lymphomas demonstrate common mutations of
members in the NOTCH, B-cell receptor (BcR), and NF-κB
signaling pathways (Table 1).63,64 Similarly, different PTCL
subtypes, such as mycosis fungoides and Sézary syn-
drome, AITL and other TFH-derived PTCL, and adult T-cell
leukemia/lymphoma (ATLL) share frequent alterations
affecting both epigenetic regulation and T-cell receptor
NGS-based diagnostics in lymphomas
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Table 1B. Mutation frequencies in different T-cell lymphoma entities.
Pathway/cellular function AITL MF/SS PTCL-NOS LGL HSTL P-TLL ALK-neg ALCL NKTCL ATLL
Co-stimulatory/TCR signaling elements
CD28 11% - - - - - - - 2%
FYN 3% - - - - - - - 3%
PLCG1 12% 20% 15% - - - - - 36%
Epigenetic modifiers
TET2 50-70% - 20-48° - - - - - -
IDH2 20-40% - - - - - - - -
DNMT3 20-30% - 10-27° - - - - - -
JAK-STAT signaling pathway - - - - - -
STAT3 - - - 35% - - 38%# 5-10% 22%
STAT5B (N642H)* - - - <5% 25% 35% -6% -
JAK1 - - - - - <10% 38%# - -
JAK3 - - - - - 30-40% -20% -
NF-κB signaling pathway
PRKCB - - - - - - - - 33%
CARD11 - 15% - - - - - - 24%
TNFRSF1B - 6% - - - - - - -
Other genes 
RHOA (G17V)¤ 60-70% 7% 18%° - - - - - <15%
DDX3X - - - - - - -20% -
CCR4 - 7% - - - - - - -
AITL: angioimmunoblastic T-cell lymphoma; MF: mycosis fungoides, SS: Sézary syndrome; PTCL-NOS: peripheral T-cell lymphoma not otherwise specified; LGL: large granular lymphocytic
leukemia; HSTL: hepatosplenic T-cell lymphoma; T-PLL: T-cell prolymphocytic leukemia; ATLL: adult T-cell leukemia/lymphoma; ALK-neg ALCL: ALK-negative anaplastic large cell lymphoma,
NKTCL, extranodal NK/T-cell lymphoma, nasal-type. *STAT5B mutations were also reported in 36% of EATL type 2 (Kücück et al Nat Commun 2015107). °Mutations in TET2, RHOA and DNMT3A
also reported in the subgroup of PTCL-NOS with TFH phenotype. #38% of systemic ALK-negative ALCL patients were reported to carry both JAK1 and STAT3 mutations (Crescenzo et al, Cancer
Cell 201565). ¤Whereas RHOA mutations in AITL almost invariably involve the hotspot G17V, RHOA mutations in ATLL are more widely distributed (Kataoka et al, Nat Genet, 201556; Nagata et
al, Blood 2016108).
(TCR) signaling, whereas mutations of members of the
JAK-STAT signaling pathway (STAT3, STAT5B) are shared
by several cytotoxic T-cell or NK-cell lymphomas, such as
T-LGL, nasal NK/T-cell lymphomas, hepatosplenic T-cell
lymphoma, enteropathy-associated T-cell lymphoma
(type 2) and ALK-negative anaplastic large cell lym-
phomas11,56,65,66 (Table 1). 
Subgroups of patients within a lymphoma entity may
also display differential mutation profiles, initially shown
for the GCB vs. ABC subtypes of DLBCL (Table 1) and,
more recently, also demonstrated in other lymphomas e.g.
HCL, where cases expressing the IGHV4-34 gene in the
clonotypic B-cell receptor lack the canonical BRAFV600E, and
instead display enrichment for MAP2K1 mutations with
an overall similar profile to the HCL-variant.67,68 Similarly, a
subgroup of SMZLs with IGHV1-2 expressing B-cell
receptor commonly harbors inactivating KLF2 mutations
and 7q deletions.16,17 Potentially, this might aid future diag-
nostics aiming to distinguish these subtypes, however the
utility and applicability of this approach have to be stud-
ied further. 
In summary, presently, MYD88, BRAF, ID3, TCF3,
STAT3, STAT5B, RHOA, TET2, and IDH2 mutations are
the only genes that can be considered as a complement to
the current set-up for lymphoma diagnostics. However,
the list is rapidly expanding as evidenced by the case of
RRAGC mutations, for example.  
III. Genes with prognostic potential
Several gene mutations have been associated with clini-
cal outcome in various lymphoma subtypes. In CLL,
besides TP53 and ATMmutations, which are both known
to confer poor prognosis, recent high-throughput NGS
studies have revealed recurrent mutations within
NOTCH1, SF3B1, and BIRC3 for example, that were
reported to be associated with poor clinical outcome with
higher frequencies in relapsing/treatment-refractory CLL
and in Richter’s syndrome.48,69-79 More recent studies have
also identified additional gene mutations that may confer
a worse outcome in CLL, e.g. NKFBIE, EGR2, and RPS15,
although they have been studied less.78-79 In a recent multi-
center study conducted within ERIC, sequencing of TP53,
NOTCH1, SF3B1, BIRC3 and MYD88 was performed in a
large patient series (totaling 3,490 patients), revealing that
TP53 and SF3B1 mutations, but not NOTCH1 mutations,
remained as independent prognostic markers of shorter
time to first treatment in multivariate analysis, even
amongst patients expressing unmutated IGHV genes.50 A
few published clinical trials have also pointed to a prog-
nostic and even predictive role of SF3B1 and NOTCH1
mutations in CLL,28 where, in particular, the latter confers
resistance to the anti-CD20 monoclonal antibodies ritux-
imab29 and ofatumumab,80 however, this needs further
exploration and validation. Currently, as a new ERIC proj-
ect, a dedicated NGS-based gene panel (including 11
genes) has been designed with the purpose to test differ-
ent targeted enrichment techniques and evaluate inter-
center variability and reproducibility. 
Similar gene panel-based efforts have also been per-
formed for SMZL, revealing a high frequency of TP53,
KLF2, NOTCH2, TNFAIP3, and MYD88mutations,17,18 and
demonstrating NOTCH2 and TP53 mutations as inde-
pendent markers of short treatment-free and overall sur-
vival, respectively.16 Nonetheless, caution is required given
the retrospective nature of the published studies and the
overall rarity of SMZL raising concerns about potential
selection biases. 
MCL is characterized by a relatively high number of
recurrent secondary genomic aberrations, but few of them
have demonstrated additional prognostic value. From
recent NGS studies, the prognostic value of
NOTCH1/NOTCH2 mutations was recently highlight-
ed7,81 in addition to TP53 defects.
In DLBCL, the prognostic impact of MYC translocations
critically depends on the second hit, with cases harboring
TP53mutation and MYC translocation showing the worst
overall survival, followed by those cases carrying MYC
and BCL2 translocation.82,83 Indeed, DLBCL with TP53
mutation and MYC translocation is a newly recognized
subset of ‘double-hit’ lymphoma, accounting for one-third
of MYC translocation positive DLBCL. Hence, it is pivotal
to perform TP53 mutation screening, in addition to the
detection of BCL2 translocation in MYC translocation pos-
itive DLBCL, in order to distinguish the double-hit DLBCL
from those with an isolated MYC translocation.84
Among PTCL, TET2 mutations in AITL patients were
reported to associate with a more aggressive clinical pres-
entation and a shorter progression-free survival,53 whereas
in a recent study of NK-TCL DDX3Xmutations conferred
a particularly poor prognosis.85
Considering the significant differences in mutation fre-
quencies observed between different studies, best exem-
plified by DLBCL, large-scale efforts are now needed, in
particular for rarer entities, to fully understand which
genes are the most relevant and will retain independent
prognostic impact in relation to other known clinical/mol-
ecular markers. This is particularly relevant in light of
recent studies86-88 pointing to a prognostic relevance of par-
ticular combinations of mutations and/or an increasing
R. Rosenquist et al.
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Table 2. Categorization of gene mutations based on current evidence levels.
Category Gene mutations
1. Immediate impact TP53 mutations (exons 4-10) in CLL
on patient care
2. Diagnostic impact MYD88L265P mutation in WM/LPL
BRAFV600E mutation in HCL 
KLF2 mutations in SMZL
ID3 and TCF3 mutations in BL
STAT3 mutations in LGLL 
RHOA, TET2, IDH2 and DNMT3A mutations  
in AITL and other TFH-derived PTCL
3. Prognostic impact CLL: TP53, ATM, BIRC3, NFKBIE, NOTCH1, SF3B1
MCL: TP53, NOTCH1, NOTCH2 mutations
SMZL: NOTCH2, TP53 mutations
DLBCL: TP53 mutation & MYC translocation
NKTCL: DDX3X mutations
4. Potential clinical impact Therapy response to BcR inhibitors:
in the near future WM: MYD88, CXCR4 mutations
DLBCL: CD79B mutations (responsive)
CARD11, MYD88 mutations 
(non-responsive)
Resistance to BcR inhibitors: 
BTKC481S, PCLG2 mutations
New inhibitors under development:
EZH2, SF3B1 & NOTCH1
aBased on references listed in Table 1. CLL: chronic lymphocytic leukemia; WM:  Waldenström’s
Macroglobulinemia; LPL: lymphoplasmacytic lymphoma; HCL: hairy-cell leukemia; BL: Burkitt lym-
phoma; AITL: angioimmunoblastic T-cell lymphoma; MCL: mantle cell lymphoma; SMZL: splenic
marginal zone lymphoma; DLBCL: diffuse large B-cell lymphoma; NKTCL: NK T-cell lymphoma. 
number of ‘driver mutations’. In addition, the time point
of mutation screening may also differ depending on the
disease entity and response to therapy.  
IV. Genes with potential clinical impact 
in the near future
Recent studies in different lymphoma subtypes have
highlighted relevant associations between certain recurrent
gene mutations and response to treatment. The most strik-
ing example is perhaps offered by MYD88 and CXCR4
mutations, which were shown to affect responses to ibruti-
nib in WM. Indeed, patients with MYD88L265PCXCR4WT
(with WT indicating wild-type) status had 100% overall
response rate (91% major response rate) as opposed to 86%
(62%) and 71% (29%) for MYD88L265PCXCR4WHIM and
MYD88WTCXCR4WT patients, respectively.89 Although these
results were obtained from a small cohort of patients with
WM, they offer a tantalizing glimpse into the future of lym-
phoma treatment with novel companion diagnostics tai-
lored to novel therapeutic agents. 
From recent studies, we have also learnt that mutations
within the BTK (C481S) and PLCG2 genes may emerge in
CLL patients relapsing after and/or refractory to ibrutinib
treatment, and we foresee that the assessment of these
genes may soon be incorporated in the diagnostic set-up.90
Preliminary results also indicate that the divergent respons-
es of patients with MCL or DLBCL to ibrutinib may be
linked to distinct profiles of genomic aberrations, e.g. BIRC3
mutations in MCL91 and isolated MYD88 mutation in
DLBCL92 as well as mutations downstream of BTK, such as
activating mutations of CARD11 in DLBCL,93,94 may make
these tumors resistant to BTK inhibition. 
Recent reports of genes linked to particular physiological
processes have revealed new types of mechanisms that
may be suitable for targeted therapy. For mutant BRAF, the
inhibitor vemurafenib is already in clinical trials in
relapsed/refractory HCL, demonstrating high activity even
among heavily pre-treated patients.3,95 New types of prom-
ising inhibitors have also been developed for EZH2 (a his-
tone methyl transferase),96 SF3B1 (a splicing factor),97
NOTCH198 and IDH2,99 and in some cases have already
entered early phase clinical trials. The high frequency of
TET2 and/or DNMT3A mutations in AITL and other TFH-
derived PTCL may also support the rationale to use
demethylating agents as an alternative way to treat
patients, supported by the results of a recent single report.100
More generally, targeting certain epigenetic abnormalities
or alterations in pathways frequently involved in patients
with PTCL (TCR, JAK-STAT, NF-κB; Table 2) represents an
attractive approach, also taking into consideration the over-
all poor outcome of the majority of such patients with con-
ventional chemotherapy-based approaches. 
In conclusion, we expect that the list of potential thera-
peutic targets will expand quickly in coming years, once
markers have been functionally validated and new com-
pounds have been discovered.  
V. Genes for research purposes only
Finally, for most recurrently mutated genes identified
thus far, we do not yet understand their functional role
and/or their clinical association, either alone or in the pres-
ence of cooperating events. These genes might still be of
interest, however, before large-scale studies are per-
formed, it will not be possible to discern their potential
contribution to disease pathobiology. Having said that,
and similar to category IV above, this subgroup of genes
will be a ‘moving target’ depending on the evidence level
ascertained for a particular mutation in the coming years,
and genes may be taken out if a certain type of mutation
is judged to have minor impact for a specific lymphoma
entity.
How to move forward in the diagnostic field
using NGS?
As mentioned, targeted NGS allows us to select and test
many genes and samples simultaneously, and this approach
has now been validated for CLL, SMZL and DLBCL,
amongst others. In addition, targeted NGS permits a high
sequence read depth, an important factor for studying
minor subclones and thus clonal heterogeneity, and can also
be adapted to formalin-fixed, paraffin-embedded (FFPE)
tumor material, which in reality is the source of material for
most diagnostic lymphoma specimens. 
To gain further insight into NGS-based diagnostics in
lymphoma, the EGNL Group has participated in the design
of a lymphoma gene panel, compatible with FFPE material,
that includes 30 recurrently mutated genes. Our ambition
now is to perform a multi-center validation study using a
defined number of matched FFPE/fresh-frozen lymphoma
specimens to set the technical requirement for NGS-based
diagnostics (including metrics such as sequence coverage,
specificity, sensitivity and reproducibility of the technique).
Once validated, large-scale international collaborative
efforts can be conducted for each lymphoma entity, in par-
ticular within ongoing or planned treatment studies, to fully
understand how to adapt and implement NGS-based diag-
nostics in day-to-day routine diagnostics.  
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